A5048487071- Nausea and vomiting management
- Lung Cancer Treatments and Mutations
- Anesthesia and Pain Management
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Pathogenesis and Treatment of Hiccups
- Chemotherapy-induced organ toxicity mitigation
- Cancer survivorship and care
- Pharmacological Effects and Toxicity Studies
- Childhood Cancer Survivors' Quality of Life
- Cancer therapeutics and mechanisms
- Occupational and environmental lung diseases
- Colorectal Cancer Treatments and Studies
- Multiple and Secondary Primary Cancers
- Palliative Care and End-of-Life Issues
- Cancer Immunotherapy and Biomarkers
- Economic and Financial Impacts of Cancer
- Anesthesia and Sedative Agents
- Health Systems, Economic Evaluations, Quality of Life
- Global Cancer Incidence and Screening
- Neutropenia and Cancer Infections
- Neuroendocrine Tumor Research Advances
- Pituitary Gland Disorders and Treatments
- Nutrition and Health in Aging
Jacobi Medical Center
2014-2025
Albert Einstein College of Medicine
2013-2024
Ochsner Medical Center
1993-2023
The Bronx Defenders
2019
Royal North Shore Hospital
2015
St George Hospital
2015
Liverpool Hospital
2015
National Health and Medical Research Council
2015
Montefiore Medical Center
2012-2014
National Taiwan University
2013
PURPOSE: To evaluate whether treatment with single-agent docetaxel would result in longer survival than best supportive care patients non–small-cell lung cancer who had previously been treated platinum-based chemotherapy. Secondary end points included assessment of response (docetaxel arm only), toxicity, and quality life. PATIENTS AND METHODS: Patients performance statuses 0 to 2 stage IIIB/IV either measurable or evaluable lesions were eligible for entry onto the study if they undergone...
Topotecan and cyclophosphamide, doxorubicin, vincristine (CAV) were evaluated in a randomized, multicenter study of patients with small-cell lung cancer (SCLC) who had relapsed at least 60 days after completion first-line therapy.Patients received either topotecan (1.5 mg/m2) as 30-minute infusion daily for 5 every 21 (n = 107) or CAV (cyclophosphamide 1,000 mg/m2, doxorubicin 45 2 mg) infused on day 1 104). Eligibility included the following: bidimensionally measurable disease, Eastern...
In early clinical trials with patients receiving highly emetogenic chemotherapy, the neurokinin antagonist aprepitant significantly enhanced efficacy of a standard antiemetic regimen consisting type-three 5-hydroxytryptamine and corticosteroid. This multicenter, randomized, double-blind, placebo-controlled phase III study was performed to establish definitively superiority versus therapy in prevention chemotherapy-induced nausea vomiting (CINV).Patients cisplatin > or = 70 mg/m2 for first...
To update the 1999 American Society of Clinical Oncology guideline for antiemetics in oncology.The Update Committee completed a review and analysis data published from 1998 thru February 2006. The literature focused on randomized controlled trials, systematic reviews meta-analyses phase II III trials.The three-drug combination 5-hydroxytryptamine-3 (5-HT(3)) serotonin receptor antagonist, dexamethasone, aprepitant is recommended before chemotherapy high emetic risk. For persons receiving...
In a study of the effectiveness high intravenous doses metoclopramide as an antiemetic, 41 patients with advanced cancer who were being treated cisplatin entered into two double-blind trials. first trial randomly assigned to receive either or placebo, and in second they received prochlorperazine. Patients given had significantly fewer episodes emesis than placebo (medians, 1.0 vs. 10.5; P = 0.001) prochlorperazine 1.5 12.0; 0.005). Metoclopramide was superior reducing volume (P 0.001 0.022,...
Article Tools ASCO SPECIAL ARTICLE OPTIONS & TOOLS Export Citation Track Add To Favorites Rights Permissions COMPANION ARTICLES No companion articles CITATION DOI: 10.1200/JCO.1999.17.9.2971 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 10561376 Recommendations for the Use Antiemetics: Evidence-Based, Practice Guidelines Richard J. GrallaxRichard GrallaSearch by this author , David OsobaxDavid OsobaSearch Mark G. KrisxMark KrisSearch Peter...
Purpose This is the first study in which NK 1 -receptor antagonist, aprepitant (APR), was evaluated for prevention of chemotherapy-induced nausea and vomiting (CINV) with moderately emetogenic chemotherapy. Patients Methods Eligible breast cancer patients were naive to chemotherapy treated cyclophosphamide ± doxorubicin or epirubicin. randomly assigned either an regimen (day 1, APR 125 mg, ondansetron (OND) 8 dexamethasone 12 mg before OND hours later; days 2 through 3, 80 qd) a control 20...
Abstract We looked for the presence of anti‐Hu antibody in sera from 50 normal subjects; 44 patients with small cell lung cancer, not associated paraneoplastic disease; and 25 cancer sensory neuropathy, encephalomyelitis, or both. Using avidin‐biotin immunoperoxidase method a highly sensitive quantitative Western blot analysis, was detected human sera. Seven but no syndrome had detectable levels (average titer, 76 U/ml) on blot. These are significantly lower than average titer who neuropathy...
Eighty-five patients with advanced squamous carcinoma or adenocarcinoma of the lung were randomly assigned to receive vindesine either high dose (120 mg/m2 body surface area) low (60 mg/m2) cisplatin. All had measurable disease and not previously received chemotherapy. The response rate was similar both treatments (43% complete partial remission rate), but cisplatin regimen superior in median duration (12 versus 5.5 months; p = 0.05) survival for responding (21.7 10 0.02). Myelosuppression...
Although many trials have evaluated the severity and treatment of nausea vomiting immediately after cisplatin administration, no studies focused on occurring more than 24 hours chemotherapy--delayed emesis. Two consecutive were undertaken to evaluate incidence, course (trial 1), 2) delayed emesis develop methods study these conditions. Eighty-six patients receiving (120 mg/m2) for first time entered. On day treatment, all received intravenous (IV) metoclopramide (3 mg/kg X 2 doses) plus...
BackgroundNEPA is a novel oral fixed-dose combination of netupitant (NETU), new highly selective neurokinin-1 (NK1) receptor antagonist (RA) and palonosetron (PALO), pharmacologically clinically distinct 5-hydroxytryptamine type 3 (5-HT3) RA. This study was designed to determine the appropriate clinical dose NETU combine with PALO for evaluation in phase NEPA program.Patients methodsThis randomized, double-blind, parallel group 694 chemotherapy naïve patients undergoing cisplatin-based solid...
To evaluate whether treatment with single-agent docetaxel would result in longer survival than best supportive care patients non-small-cell lung cancer who had previously been treated platinum-based chemotherapy. Secondary end points included assessment of response (docetaxel arm only), toxicity, and quality life.
The 2015 MASCC–ESMO guideline for the prevention of ChT- and RINV was updated based on a literature search from 1 June through 31 January 2023. Thirty-four multidisciplinary experts reviewed literature. most important updates were as follows:1)Recommendation to use olanzapine part prophylaxis patients receiving HEC;2)Recommendation 1-day DEX schedule in treated with AC, carboplatin or other MEC;3)Suggestion include an NK1-RA antiemetic regimen women aged ≤50 years oxaliplatin;4)Suggestion...
The localization of substance P in brain-stem regions associated with vomiting, and the results studies ferrets, led us to postulate that a neurokinin-1-receptor antagonist would be an antiemetic patients receiving anticancer chemotherapy.In multicenter, double-blind, placebo-controlled trial involving 159 who had not previously received cisplatin, we evaluated prevention acute emesis (occurring within 24 hours) delayed (on days 2 5) after single dose cisplatin therapy (70 mg or more per...
To determine the frequency and prognostic importance of pretreatment clinical characteristics in patients currently undergoing treatment for stage III non-small-cell lung cancer (NSCLC), data were collected on 378 receiving high-dose (120 mg/m2) cisplatin plus vinca alkaloid combination chemotherapy regimens since 1978. Variables analyzed included age, sex, weight loss, performance status, histologic subtype, presence extrathoracic metastases, number metastatic organ sites, liver, bone, or...
The majority of patients receiving cisplatin at a dose 120 mg/m2 experience delayed nausea and vomiting occurring between 24 hours after chemotherapy administration. Ninety-one who were (120 mg/m2) as initial entered into this double-blind trial. All received intravenous (IV) metoclopramide, dexamethasone, lorazepam for the control acute emesis during period from 0 to cisplatin. Patients then randomized one three treatment regimens: placebo; oral 8 mg twice daily two days, 4 days; or...